stockrow
Friday 6 November 2026
Export CAI’s income statement to Excel — free account
Caris Life Sciences,�Inc.
Caris Life Sciences,�Inc.’s revenue for fiscal 2025 (year ended December 2025) was $812.0 million, up 97.0% from fiscal 2024.
- Revenue
- +27.0%
- EPS
- −40.3%
- Free cash flow
- −140.2%
- Total debt
- +4.46%
Quarter to September 2026, against a year earlier
24.78
1.25
−4.80%
Follow CAI
Alert me
Caris Life Sciences,�Inc. (CAI) Operating margin
Caris Life Sciences,�Inc.'s operating margin over the twelve months to 30 September 2026 was 13.4%, up 7.8 percentage points from fiscal 2025 (5.56%). That is above the Biotechnology industry median of 0.00% and above the Healthcare sector median of 0.00%.
Operating margin, annual
Embed this chart
Annual newest first
| Period | Operating margin | Change (points) |
|---|---|---|
| FY2025 | 5.56% | 67.93 |
| FY2024 | −62.4% | 42.01 |
| FY2023 | −104.4% | — |
Quarterly newest first
| Period | Operating margin | Change (points) |
|---|---|---|
| Sep 2026 | 7.01% | (3.20) |
| Jun 2026 | 10.2% | 7.77 |
| Mar 2026 | 2.44% | (27.75) |
| Dec 2025 | 30.2% | 15.14 |
| 5 more quarters | Free account |
Operating margin against peers
| Company | Operating margin |
|---|---|
| KRYS Krystal Biotech, Inc. compare | 48.4% |
| PTGX Protagonist Therapeutics, Inc. compare | 20.7% |
| TGTX TG Therapeutics, Inc. compare | 17.1% |
| CAI Caris Life Sciences,�Inc. | 13.4% |
| SYRE Spyre Therapeutics, Inc. compare | 0.00% |
| MDGL Madrigal Pharmaceuticals, Inc. compare | −10.7% |
| TWST Twist Bioscience Corporation compare | −33.6% |
| IBRX ImmunityBio, Inc. compare | −151.9% |
| CYTK Cytokinetics, Incorporated compare | −625.2% |
| Biotechnology industry median | 0.00% |
| Healthcare sector median | 0.00% |
| Market median | 0.00% |
What Operating margin is
EBIT Margin tells an investor how much operating profit, before interest and taxes, a company keeps from each unit of revenue.
EBIT ÷ Revenue
More on CAI
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Shares outstanding
- Book value per share
- The full statement